Press Releases Year None20212020201920182017 Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Operational Updates May 05, 2021 Turning Point Therapeutics to Host First Quarter 2021 Conference Call Apr 26, 2021 Turning Point Therapeutics Initiates Global Phase 1/2 Forge-1 Clinical Study of TPX-0131, a Next-Generation ALK Inhibitor Apr 12, 2021 Turning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates Apr 09, 2021 Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of RET Inhibitor TPX-0046 Apr 05, 2021 Turning Point Therapeutics Announces Board Changes Mar 31, 2021 Turning Point Therapeutics to Present New Preclinical Data For Three Drug Candidates at American Association For Cancer Research Annual Meeting Mar 10, 2021 Turning Point Therapeutics to Participate in Upcoming Investor Conferences Mar 04, 2021 Turning Point Therapeutics Reports Fourth-Quarter and Full-Year Financial Results, Provides Operational Updates Mar 01, 2021 Turning Point Therapeutics to Host Fourth Quarter and Full-Year 2020 Conference Call Feb 18, 2021 Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 14
Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Operational Updates May 05, 2021
Turning Point Therapeutics Initiates Global Phase 1/2 Forge-1 Clinical Study of TPX-0131, a Next-Generation ALK Inhibitor Apr 12, 2021
Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of RET Inhibitor TPX-0046 Apr 05, 2021
Turning Point Therapeutics to Present New Preclinical Data For Three Drug Candidates at American Association For Cancer Research Annual Meeting Mar 10, 2021
Turning Point Therapeutics Reports Fourth-Quarter and Full-Year Financial Results, Provides Operational Updates Mar 01, 2021
